8 sourcesUpdated Sep 24, 2026
The U.S. Food and Drug Administration on Thursday, Sept. 24, 2026, approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes to be used with diet and exercise. The decision was based on four late-stage trials enrolling more than 3,400 adults. In each study Onswik met the main goal, showing A1C reductions—a measure of average blood sugar—not inferior to daily basal insulin glargine, sold under brands including Sanofi’s Lantus and Lilly’s Basaglar.
Lilly said weekly dosing could cut more than 300 injections a year compared with once-daily basal insulin and that Onswik will be available in the U.S. in coming months as a pre-filled KwikPen in 500 units/mL and 1,000 units/mL concentrations. The company said Onswik should not be used in patients with type 1 diabetes because of an increased risk of severe hypoglycemia. Onswik had already won approvals in Europe, Japan and Mexico. In March 2026 the FDA approved Novo Nordisk’s insulin Awiqli for adults with type 2 diabetes.
Contested: none found.
